Akili

Recent Finacing

Series C

Recent Raise

$55M

Akili develops clinically validated, software-based therapeutics and diagnostic tools for cognitive and neurological disorders delivered via adaptive action-video-game interfaces and conducts clinical trials across ADHD, autism, depression, and neurodegeneration.